Alkem Laboratories
Alkem Laboratories Limited, a prominent player in the pharmaceutical industry, is headquartered in Mumbai, India. Founded in 1973, the company has established a strong presence in various operational regions, including North America, Europe, and Asia. Alkem is renowned for its extensive portfolio of generic and branded formulations, as well as active pharmaceutical ingredients (APIs), catering to diverse therapeutic areas such as anti-infectives, cardiology, and gastroenterology. With a commitment to quality and innovation, Alkem Laboratories has achieved significant milestones, including numerous approvals from regulatory authorities worldwide. The company is recognised for its robust research and development capabilities, which underpin its unique product offerings. Alkem's market position is further solidified by its consistent growth and notable achievements, making it a trusted name in the global healthcare landscape.
DitchCarbon Score
How does Alkem Laboratories's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Alkem Laboratories's score of 20 is lower than 83% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Alkem Laboratories's reported carbon emissions
In 2024, Alkem Laboratories reported total carbon emissions of approximately 101,568,000 kg CO2e, comprising 19,249,000 kg CO2e from Scope 1 and 82,319,000 kg CO2e from Scope 2 emissions. This data reflects a consistent reporting of emissions over the past few years, with similar figures reported in 2023, where total emissions were also about 101,568,000 kg CO2e. Alkem Laboratories has not disclosed any Scope 3 emissions data, indicating a potential area for future reporting and improvement. The company has not set specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges, which suggests that while they are tracking emissions, they may not yet have formalised commitments to reduce them. The emissions intensity for Scope 1 and Scope 2 combined was reported at approximately 2.334e-05 kg CO2e per rupee of turnover in 2024, with a physical output intensity of about 2,140 kg CO2e per tonne. This indicates a focus on measuring emissions relative to production and revenue, which is a common practice in the pharmaceutical industry. Overall, while Alkem Laboratories has made strides in emissions reporting, the absence of reduction targets and initiatives highlights an opportunity for the company to enhance its climate commitments and align with industry standards for sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 15,773,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 78,502,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Alkem Laboratories is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
